# iShares NASDAQ US Biotechnology UCITS ETF (BTEK) **Source:** https://fundology.uk/fund/btek · ISIN IE00BYXG2H39 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 30/09/2026, BTEK (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BYXG2H39) closed at £7.87 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 30/09/2026 its total return was +45.9%, or +14.0% after UK CPIH inflation. ## Summary iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2017. It tracks the NASDAQ / Biotechnology. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£7.87** (30/09/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | BTEK | | ISIN | IE00BYXG2H39 | | Category | Technology | | Type | ETF | | Provider | iShares | | Tracks | NASDAQ / Biotechnology | | Income | Accumulating | | Ongoing charge | 0.35% a year (£35 per £10,000) | | Fund size | £659m | | Launched | 2017 | | Domicile | Ireland | ## Past returns (periods to 30/09/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +49.99% | +45.29% | income reinvested | | 3 years | +68.01% | +51.61% | income reinvested | | 5 years | +45.87% | +14.03% | income reinvested | Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published. ## Calendar-year returns Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −1.6%, 2023 +0.3%, 2024 +0.4%, 2025 +24.8%; 2026 to 30/09/2026 +25.6%. Returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +53.1%; to 30/09/2025: −0.7%; to 30/09/2024: +10.2%; to 30/09/2023: −5.4%; to 30/09/2022: −10.7%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2022 | -1.6% | -9.9% | Price | | 2023 | +0.3% | -3.7% | Price | | 2024 | +0.4% | -3.0% | Price | | 2025 | +24.8% | +20.5% | Price | | 2026 to 30/09/2026 | +25.6% | +22.1% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 19.57% | -6.11% | | 3 years | 19.60% | -23.44% | | 5 years | 18.96% | -23.44% | ## Largest fall Volatility of iShares NASDAQ US Biotechnology UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 19.6% over 1 year, 19.6% over 3 years, 19.0% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF since October 2021, in pounds: −23.4% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) since January 2021 was −21.7% (12 months to 18/02/2022); the highest was +60.6% (12 months to 03/07/2026). On 30/09/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF was at its highest weekly close since October 2021, in pounds. ## Charges compared with similar funds Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year, as of 01/10/2026: 92 of the 118 other technology funds charge more, 8 the same and 18 less (share classes counted once). ## Funds tracking the same index 3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (30/09/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | Invesco NASDAQ Biotech UCITS ETF | 0.40% | +46.1% | +62.3% | +35.2% | | iShares NASDAQ US Biotechnology UCITS ETF | 0.35% | +49.5% | +68.0% | +44.4% | | iShares NASDAQ US Biotechnology UCITS ETF (this fund) | 0.35% | +50.0% | +68.0% | +45.9% | Returns are the data vendor’s, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.35%** per year - ISA eligible: yes - SIPP eligible: yes ## Top holdings Largest positions (as of 29/09/2026): | Holding | Weight | |---|---| | Gilead Sciences | 8.25% | | Amgen | 7.85% | | Vertex Pharmaceuticals | 7.71% | | Moderna | 5.30% | | Regeneron Pharmaceuticals | 4.95% | | Revolution Medicines | 2.86% | | Illumina | 2.68% | | Alnylam Pharmaceuticals | 2.22% | | Biogen | 2.19% | | Argenx | 1.73% | ## Where it invests Shares of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed. ### By sector As published by iShares, as of 29/09/2026. | Sector | Weight | |---|---| | Health Care | 99.8% | | Cash and derivatives | 0.2% | ### By type of asset Added up from the holdings iShares publishes, as of 29/09/2026. | Type of asset | Weight | |---|---| | Equity | 100.0% | | Cash and money market | 0.2% | All 248 holdings: https://fundology.uk/fund/btek/holdings --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.